3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Ovarian Neoplasms
4
Prostatic Neoplasms
2
Fallopian Tube Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Recurrence
1
Primary Myelofibrosis
1
Pancreatic Neoplasms
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Metastatic Castration-resistant Prostate Cancer
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma
1
Leukemia
1
Glioblastoma
1
Gastrointestinal Neoplasms
1
Endometrial Neoplasms
1
Carcinoma, Transitional Cell
1
Breast Neoplasms
1
Adenocarcinoma Of Esophagus
1
Adenocarcinoma
1
Interventions
Gemcitabine
8
pembrolizumab
5
Paclitaxel
4
Capecitabine
4
Albumin-Bound Paclitaxel
4
Nivolumab
3
Fluorouracil
3
Cyclophosphamide
3
Carboplatin
3
sargramostim
2
poly ICLC
2
fludarabine
2
Prednisone
2
Oxaliplatin
2
Irinotecan
2
Hydroxychloroquine
2
Erlotinib Hydrochloride
2
Dexamethasone
2
Cisplatin
2
130-nm albumin-bound paclitaxel
2
temsirolimus
1
tegafur-gimeracil-oteracil
1
spartalizumab
1
sintilimab
1
rucaparib
1
resiquimod
1
repotrectinib
1
regorafenib
1
pralsetinib
1
olaparib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Adenocarcinoma
×
rucaparib
×
Clear all
NCT03995017
2023-02-01
RiME
University of Kansas Medical Center
Phase 1/2
Unknown
34 enrolled